文献速递乳腺MR

乳腺MRI检出的BI-RADS 3、4、5类病变的患病率与预测价值:与研究指征的相关性

Prevalence and Predictive Value of BI-RADS 3, 4, and 5 Lesions Detected on Breast MRI: Correlation with Study Indication.
PubMed 文献 · Acad Radiol · 2016-12-07

该回顾性研究分析了2009至2011年间3360例患者的5778次增强乳腺MRI检查,共9216个乳腺BI-RADS评估。诊断性指征检查的BI-RADS 3、4、5类频率及BI-RADS 4、5类的阳性预测值(PPV2)均高于筛查指征。BI-RADS 3类病变的总体恶性率为1.9%,不同检查指征间无差异。作者认为乳腺MRI审计应像乳腺X线摄影一样按检查指征分开进行。

要点

  • 诊断性指征乳腺MRI的BI-RADS 3、4、5类频率均高于筛查指征(P<0.01)。
  • BI-RADS 4、5类活检病变中恶性占31.5%(209/663),良性占68.5%(454/663)。
  • BI-RADS 3类总体恶性率为1.9%,诊断性与筛查指征间无差异(P=0.76)。

核心结论

  • 诊断性指征乳腺MRI的异常解读率和BI-RADS 4、5类PPV2均高于筛查指征;BI-RADS 3类恶性率在不同指征间无差异;乳腺MRI审计应按检查指征分开进行。

研究设计与样本

  • 经机构审查委员会批准、符合《健康保险流通与责任法案》的回顾性综述,分析2009至2011年乳腺MRI数据库中3360例患者的5778次增强检查,共9216个BI-RADS评估;本机构对每侧乳腺分别进行BI-RADS评估;采用Fisher精确检验和卡方检验进行单变量分析。

诊断标准与关键数值

  • 共9216个BI-RADS评估:BI-RADS 1和2类7879个(85.5%),BI-RADS 3类567个(6.2%),BI-RADS 4类715个(7.8%),BI-RADS 5类55个(0.6%);诊断性指征BI-RADS 3、4、5类频率分别为7.8%、14.6%、1.6%,筛查指征分别为5.2%、4.0%、0.1%(P<0.01);663个BI-RADS 4和5类病变活检,恶性209个(31.5%)、良性454个(68.5%);BI-RADS 3类总体恶性率1.9%(11/567),诊断性1.6%、筛查2.3%(P=0.76);BI-RADS 4和5类PPV2诊断性29.1%(154/530)、筛查22.9%(55/240)。

临床应用与阅片要点

  • 作者认为乳腺MRI审计应像乳腺X线摄影一样按检查指征分开进行;本机构对每侧乳腺分别进行BI-RADS评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: This study aims to determine the prevalence and predictive value of Breast Imaging Reporting and Data System (BI-RADS) 3, 4, and 5 findings on breast magnetic resonance imaging (MRI) and to evaluate the impact of study indication on the predictive value of BI-RADS categories.

MATERIALS AND METHODS: This institutional review board approved, Health Insurance Portability and Accountability Act (HIPAA) compliant retrospective review of our breast MRI database from 2009 to 2011, of 5778 contrast-enhanced studies in 3360 patients was performed. At our institution, each breast receives an individual BI-RADS assessment. Breast MRI reports and electronic medical records were reviewed to obtain BI-RADS assessment, patient demographics, and outcomes. Univariate analysis was performed with Fisher exact and chi-square tests.

RESULTS: A total of 9216 BI-RADS assessments were assigned during the study period: 7879 (85.5%) BI-RADS 1 and 2, 567 (6.2%) BI-RADS 3, 715 (7.8%) BI-RADS 4, and 55 (0.6%) BI-RADS 5 assessments. The frequency of BI-RADS 3, 4, and 5 assessments was higher in studies performed for diagnostic (7.8%, 14.6%, 1.6%, respectively) than screening (5.2%, 4.0%, 0.1%) indications (P < 0.01). A total of 663 BI-RADS 4 and 5 lesions were biopsied with 209 (31.5%) malignant and 454 (68.5%) benign outcomes. The overall cancer rate for BI-RADS 3 findings was 1.9% (11 of 567) with no difference observed by study indication (diagnostic, 1.6%; screening, 2.3%; P = 0.76). The positive predictive value (PPV2) of BI-RADS 4 and 5 was higher for diagnostic (29.1%, 154 of 530) than for screening (22.9%, 55 of 240) indications.

CONCLUSIONS: Abnormal interpretation rates and PPV2 for MRIs performed for diagnostic indications are higher than for screening indications. Similar to mammography, breast MRI audits should be separated by study indication.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Chikarmane SA, Tai R, Meyer JE, et al. Prevalence and Predictive Value of BI-RADS 3, 4, and 5 Lesions Detected on Breast MRI: Correlation with Study Indication. Acad Radiol. 2016. PMID: 27955878. doi:10.1016/j.acra.2016.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。